Thrombosis risk factor modifications: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Thrombosis}} | {{Thrombosis}} | ||
In patients with known risk factor(s) of thrombosis formation with estimated danger in favor of prevention initiation in cost-effect analysis. the prevention process starts by prescribing anti-coagulant and anti-platelet drugs. For instance, the thrombosis prevention pharmacotherapy is routinely administered after major surgical procedures and in patients with hypercoagulability like antiphospholipid syndrome. | |||
==References== | ==References== | ||
Revision as of 15:55, 27 August 2018
|
Thrombosis Microchapters |
|
Site of Thrombosis |
|---|
|
Differentiating Thrombosis from other Diseases |
|
Diagnosis |
|
Treatment |
|
Thrombosis risk factor modifications On the Web |
|
Risk calculators and risk factors for Thrombosis risk factor modifications |
In patients with known risk factor(s) of thrombosis formation with estimated danger in favor of prevention initiation in cost-effect analysis. the prevention process starts by prescribing anti-coagulant and anti-platelet drugs. For instance, the thrombosis prevention pharmacotherapy is routinely administered after major surgical procedures and in patients with hypercoagulability like antiphospholipid syndrome.